AstraZeneca Rating Reiterated by JPMorgan Chase & Co. (AZN)
AstraZeneca (LON:AZN)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday, Stock Ratings Network reports. They currently have a GBX 3,300 ($52.68) price target on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 3.68% from the company’s current price.
Shares of AstraZeneca (LON:AZN) traded down 0.11% on Tuesday, hitting GBX 3183.00. The stock had a trading volume of 1,437,462 shares. AstraZeneca has a one year low of GBX 2786.00 and a one year high of GBX 3544.50. The stock has a 50-day moving average of GBX 3215.42 and a 200-day moving average of GBX 3252.57. The company’s market cap is £39.851 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,220 ($51.40) price target on the stock. Separately, analysts at Jefferies Group downgraded shares of AstraZeneca from a “hold” rating to an “underperform” rating in a research note to investors on Friday. Finally, analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday, October 10th. They now have a GBX 3,213 ($51.29) price target on the stock. Twelve investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of GBX 3,103.98 ($49.55).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.